The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
At its annual health event on Tuesday, Google announced a series of changes to its search tool that it said will make it easier to access information about affordable health care services.
The Environmental Protection Agency (EPA) is proposing the nation's first-ever drinking water standard around polyfluoroalkyl substances (PFAS) or "forever chemicals."
It's Women's History Month and Tuesday marks Equal Pay Day. To honor the occasion, Laura Gassner Otting, author of Limitless: How to Ignore Everybody, Carve Your Own Path, and Live Your Best Life, spoke with Cheddar News' correspondent Shannon LaNier about how to properly value yourself and get the pay you deserve, regardless of your gender.
Southwest Airlines Co. on Tuesday outlined a plan to strengthen its operational resilience after a winter storm late last year led to widespread cancellations and delays.
Novo Nordisk has announced that it's cutting the price of pre-filled insulin pens and vials by up 75 percent for people living with diabetes starting in January 2024.
